These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 32781983)

  • 1. Treatment patterns and comorbid burden of patients newly diagnosed with multiple sclerosis in the United States.
    Kern DM; Cepeda MS
    BMC Neurol; 2020 Aug; 20(1):296. PubMed ID: 32781983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis.
    Bove R; Applebee A; Bawden K; Fine C; Shah A; Avila RL; Belviso N; Branco F; Fong K; Lewin JB; Liu J; England SM; Vignos M
    Mult Scler Relat Disord; 2024 Aug; 88():105738. PubMed ID: 38959591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world disease-modifying therapy pathways from administrative claims data in patients with multiple sclerosis.
    Fox RJ; Mehta R; Pham T; Park J; Wilson K; Bonafede M
    BMC Neurol; 2022 Jun; 22(1):211. PubMed ID: 35672686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
    Zhang T; Tremlett H; Leung S; Zhu F; Kingwell E; Fisk JD; Bhan V; Campbell TL; Stadnyk K; Yu BN; Marrie RA;
    Neurology; 2016 Apr; 86(14):1287-1295. PubMed ID: 26944268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.
    Wijnands JMA; Zhu F; Kingwell E; Fisk JD; Evans C; Marrie RA; Zhao Y; Tremlett H
    J Neurol Neurosurg Psychiatry; 2018 Oct; 89(10):1050-1056. PubMed ID: 29602795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
    Oleen-Burkey M; Cyhaniuk A; Swallow E
    BMC Neurol; 2014 Jan; 14():11. PubMed ID: 24423119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
    Bonafede MM; Johnson BH; Wenten M; Watson C
    Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
    Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics of Multiple Sclerosis Disease-Modifying Therapies in the USA.
    Hartung DM
    Curr Neurol Neurosci Rep; 2021 May; 21(7):28. PubMed ID: 33948740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations.
    Evans C; Marrie RA; Zhu F; Leung S; Lu X; Kingwell E; Zhao Y; Tremlett H
    Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):702-711. PubMed ID: 28370875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-modifying therapy usage in patients with multiple sclerosis in France: A 6-year population-based study.
    Leblanc S; Roux J; Tillaut H; Le Page E; Leray E
    Rev Neurol (Paris); 2021 Dec; 177(10):1250-1261. PubMed ID: 34253346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021.
    Swital M; Drouin J; Miranda S; Bakchine S; Botton J; Dray-Spira R
    Mult Scler; 2024 Feb; 30(2):227-237. PubMed ID: 38281078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health care services and disease modifying therapies use in community-based multiple sclerosis patients: Evolution from 2013 to 2015 and demographic characteristics.
    Ha-Vinh P; Nauleau S; Clementz M; Régnard P; Sauze L; Clavaud H
    Presse Med; 2019 Jan; 48(1 Pt 1):e1-e19. PubMed ID: 30528148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease modifying therapies continue to drive up health care cost among individuals with multiple sclerosis.
    Kim Y; Krause TM; Blum P; Freeman L
    Mult Scler Relat Disord; 2019 May; 30():69-75. PubMed ID: 30738875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis.
    Parks NE; Andreou P; Marrie RA; Fisk JD; Bhan V; Kirkland SA
    Mult Scler Relat Disord; 2021 Nov; 56():103249. PubMed ID: 34517192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
    Coyle PK; Gorritz M; Wade RL; Zhou Z; Khalid S; Maiese EM; Deshpande C; Shao QS
    Mult Scler Relat Disord; 2023 Oct; 78():104881. PubMed ID: 37556938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors influencing patients' willingness-to-pay for disease-modifying therapies for multiple sclerosis.
    Poudel N; Banjara B; Kamau S; Frost N; Ngorsuraches S
    Mult Scler Relat Disord; 2021 Feb; 48():102720. PubMed ID: 33429304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy.
    Marangi A; Farina G; Vicenzi V; Forlivesi S; Calabria F; Marchioretto F; Forgione A; Rossi F; Stenta G; Vianello M; Gajofatto A; Benedetti MD
    Mult Scler Relat Disord; 2020 Jun; 41():102004. PubMed ID: 32078935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.